# Ovarian Cancer Epigenetics, Immunity and Therapy

> **NIH NIH R01** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2020 · $621,601

## Abstract

Tumors characterized by limited Th1-type chemokine (e.g.CXCL9 and CXCL10) expression and low frequency
of effector tumor infiltrating lymphocytes (TIL) in the microenvironment, render immune-cell-targeted regimens
less likely to succeed. In patients with high grade serous ovarian cancer, a polycomb repressive complex 2
(PRC2) protein, enhancer of zeste 2 (EZH2)-based histone H3 lysine 27 trimethylation (H3K27me3) mediates
a repression on CXCL9 and CXCL10 expression. It controls effector T cell tumor trafficking and impacts
therapeutic efficacy of cancer immune therapy. Thus, epigenetic mechanism (e.g. PRC2) may control the
“hot” vs “cold” phenotype of cancer and shape immunotherapeutic efficacy.
In addition to PRC2, mammalian chromatin remodeler switch/sucrose non-fermentable (SWI/SNF) complexes
(also called BAF complex for Brg-/Brama-associated factor complex) are important epigenetic machinery. AT
-
rich interactive domain-containing protein 1A (ARID1A) is a member of the SWI/SNF complex. Potential
immunological role, immune regulatory mechanisms, immune-associated clinical significance, and
therapeutic relevance of
ARID1A
are unknown in human cancer including human ovarian cancer.
Our
preliminary data show a deficiency in the IFNγ-signaling pathway in several ARID1A mutated ovarian clear
carcinoma cells and ARID1A is required for intact CXCL9 and CXCL10 expression. Our previous work reveals
that PRC2 complex represses CXCL9 and CXCL10 expression in high grade ovarian cancer. Thus, we
hypothesize that there may be a dynamic balance between PRC2 (e.g. EZH2) and SWI/SNF (e.g. ARID1A)
complexes in the control of IFNγ-responsiveness in ovarian cancer. To test this hypothesis, our project is
to conduct comprehensive molecular, functional, translational, and clinical research on the nature of effector T
cell tumor trafficking and IFNγ-pathway in the human ovarian carcinoma microenvironment, and will provide
rich opportunities to take our understanding of effector T cell biology in the tumor to a new level of basic and
practical application. The application is highly translational. Our specific aims are:
Aim 1 is to test our hypothesis that
ARID1A
-signaling circuit controls tumor IFNγ-responsiveness
in
the tumor microenvironment.
Aim 2 is to test our hypothesis that
ARID1A
-signaling circuit associates with effector T cell tumor
trafficking, tumor immunity, and therapy

## Key facts

- **NIH application ID:** 9939484
- **Project number:** 5R01CA214911-03
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** WEIPING ZOU
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $621,601
- **Award type:** 5
- **Project period:** 2018-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9939484

## Citation

> US National Institutes of Health, RePORTER application 9939484, Ovarian Cancer Epigenetics, Immunity and Therapy (5R01CA214911-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9939484. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*